View Older Stories View More Recent Stories

Nov 5, 2025 06:17AM Kymera Therapeutics (KYMR) PT Raised to $84 at H.C. Wainwright
Nov 4, 2025 01:19PM Kymera Therapeutics (KYMR) PT Raised to $67 at Oppenheimer
Nov 4, 2025 07:04AM Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c
Nov 3, 2025 02:33AM Guggenheim Assumes Kymera Therapeutics (KYMR) at Buy
Oct 27, 2025 07:00AM Kymera presents preclinical data for oral IRF5 degrader KT-579
Oct 24, 2025 05:27AM Citi Adds Kymera Therapeutics (KYMR) to 90-Day Upside Catalyst Watch
Oct 20, 2025 04:03PM Mizuho Starts Kymera Therapeutics (KYMR) at Outperform
Oct 7, 2025 09:01AM Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Sep 30, 2025 04:29PM Kymera Therapeutics (KYMR) PT Raised to $63 at Oppenheimer
Sep 30, 2025 08:08AM Kymera Therapeutics (KYMR) PT Raised to $68 at Truist Securities
Sep 19, 2025 06:48AM Kymera Therapeutics (KYMR) PT Raised to $70 at H.C. Wainwright
Sep 17, 2025 04:35AM Barclays Starts Kymera Therapeutics (KYMR) at Overweight
Sep 16, 2025 02:30AM RBC Capital Starts Kymera Therapeutics (KYMR) at Outperform
Sep 11, 2025 05:39AM Kymera Therapeutics (KYMR) PT Raised to $88 at Wolfe Research
Aug 11, 2025 07:04AM Kymera Therapeutics (KYMR) Misses Q2 EPS by 12c
Jul 7, 2025 08:09AM Kymera Therapeutics (KYMR) PT Lowered to $65 at Brookline Capital Markets
Jul 3, 2025 04:25AM Morgan Stanley Assumes Kymera Therapeutics (KYMR) at Overweight
Jun 27, 2025 12:19PM Stifel Defending Kymera Therapeutics (KYMR): 'We see any weakness from today's news as a buying opportunity'
Jun 27, 2025 09:37AM Kymera Therapeutics (KYMR) PT Raised to $54 at BofA Securities
Jun 26, 2025 07:36AM Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright
Jun 25, 2025 04:06PM Kymera Therapeutics (KYMR) announces $250 million public offering
Jun 25, 2025 04:05PM Kymera Therapeutics (KYMR) PT Lowered to $70 at Brookline Capital Markets
Jun 25, 2025 12:43PM Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
Jun 25, 2025 10:32AM Stifel says buy Kymera Therapeutics (KYMR) on today's weakness
Jun 25, 2025 09:21AM Leerink Partners Reiterates Outperform Rating on Kymera Therapeutics (KYMR)
Jun 25, 2025 07:05AM Kymera Therapeutics (KYMR) Announces Sanofi IRAK4 Collaboration Update
Jun 25, 2025 07:02AM Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Jun 3, 2025 09:07AM UBS Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jun 3, 2025 08:13AM Kymera Therapeutics (KYMR) PT Raised to $68 at Stifel
Jun 3, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jun 3, 2025 04:49AM Wells Fargo Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
Jun 3, 2025 03:31AM B.Riley Upgrades Kymera Therapeutics (KYMR) to Buy
Jun 3, 2025 03:19AM Morgan Stanley Upgrades Kymera Therapeutics (KYMR) to Overweight
Jun 2, 2025 03:39PM Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Data
Jun 2, 2025 02:09PM Kymera Therapeutics (KYMR) PT Raised to $60 at Citi
Jun 2, 2025 02:06PM BofA Securities Upgrades Kymera Therapeutics (KYMR) to Buy
Jun 2, 2025 09:55AM Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Data
Jun 2, 2025 08:04AM Citi Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jun 2, 2025 07:00AM Kymera Therapeutics (KYMR) Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
May 30, 2025 04:02PM Kymera Therapeutics (KYMR) to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
May 20, 2025 04:28AM Stifel Resumes Kymera Therapeutics (KYMR) at Buy
May 19, 2025 12:15PM Kymera Therapeutics (KYMR) Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
May 12, 2025 08:14AM Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR)
May 12, 2025 06:11AM Kymera Therapeutics (KYMR) PT Lowered to $55 at BTIG
May 9, 2025 01:57PM Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR) Following Q1 Update
May 9, 2025 07:21AM Kymera Therapeutics (KYMR) Tops Q1 EPS by 7c
May 9, 2025 07:04AM Kymera Therapeutics (KYMR) Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Apr 29, 2025 05:58PM Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) ahead of June readout
Apr 9, 2025 07:01AM Kymera Therapeutics (KYMR) Appoints Noah Goodman as Chief Business Officer
Feb 28, 2025 10:57AM Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR)
View More Recent Stories View Older Stories